Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

FDA Investigating Precancer Risk Associated with Diabetes Drugs Januvia, Byetta

Filed May 10th, 2013 Joshua Sophy

People taking certain prescription drugs in the treatment of type 2 diabetes may be at risk of suffering pancreatitis and of precancerous conditions in the pancreas.

The U.S. Food and Drug Administration (FDA) is currently investigating whether diabetics prescribed incretin mimetics drugs like Byetta and Januvia face a greater risk of pancreatic duct metaplasia alongside the already announced risk of acute pancreatitis, according to a report at GastroEndoNews.com.

If the FDA confirms the findings of an unpublished study that prompted its investigation, it would add to an already dangerous safety profile for incretin mimetics and essentially most drugs prescribed in the treatment of type 2 diabetes, according to our previous reports. Drugs like Byetta and Januvia already carry warnings about the risk of acute pancreatitis and we’ve been reporting on isolated data and complaints from people taking these drugs that they may be linked to pancreatic cancer and thyroid cancer.

GastroEndoNews.com adds that the FDA will attend June’s National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute’s Pancreatitis Diabetes Pancreatic Cancer workshop. The agency will be gathering additional data on these risks and make a formal announcement sometime in the future when it can confirm some or all these risks.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!